FDA Asks Genervon To Release ALS Drug Trial Data As Pressure From Patients Builds

In response to calls from patients and others about GM604, FDA issued a public statement calling on the company to release full clinical trial data for its investigative amyotrophic lateral sclerosis drug, which recently completed a Phase IIa trial.